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Practice Pattern of Gastroenterologists for the Management of 
GERD Under the Minimal Influence of the Insurance 
Reimbursement Guideline: A Multicenter Prospective 
Observational Study
The objective of the study was to document practice pattern of gastroenterologists for the 
management of gastroesophageal reflux disease (GERD) under the minimal influence of 
the insurance reimbursement guideline. Data on management for 1,197 consecutive 
patients with typical GERD symptoms were prospectively collected during 16 weeks. In 
order to minimize the influence of reimbursement guideline on the use of proton pump 
inhibitors (PPIs), rabeprazole was used for the PPI treatment. A total of 861 patients (72%) 
underwent endoscopy before the start of treatment. PPIs were most commonly prescribed 
(87%). At the start of treatment, rabeprazole 20 mg daily was prescribed to 94% of the 
patients who received PPI treatment and 10 mg daily to the remaining 6%. At the third 
visits, rabeprazole 20 mg daily was prescribed to 70% of those who were followed and 10 
mg daily for the remaining 30%. Continuous PPI treatment during the 16-week period 
was performed in 63% of the study patients. In conclusion, a full-dose PPI is preferred for 
the initial and maintenance treatment of GERD under the minimal influence of the 
insurance reimbursement guideline, which may reflect a high proportion of GERD patients 
requiring a long-term treatment of a full-dose PPI. 
Key Words: Gastroesophageal Reflux Disease; Korea; Proton Pump Inhibitors
Kwang Jae Lee
1, Jin Il Kim
2, Ju Sang Park
3, 
Byung Sik Moon
4, Sang-Gyun Kim
5, 
Jae Hee Chun
6, Hoon-Yong Jung
7, 
Chang Hwan Choi
8, Seong Woo Chun
9, 
Geun Am Song
10, Myung Gyu Choi
2 
and Hoon Jai Chun
11
1Department of Gastroenterology, Ajou University 
School of Medicine, Suwon; 
2Department of Internal 
Medicine, the Catholic University of Korea College 
of Medicine, Seoul; 
3Department of Internal 
Medicine, Bundangjesaeng Hospital, Seongnam; 
4Department of Internal Medicine, Sejong Hospital, 
Bucheon; 
5Department of Internal Medicine, Seoul 
National University College of Medicine, Seoul; 
6Department of Internal Medicine, Yonsei University 
College of Medicine, Seoul; 
7Department of Internal 
Medicine, University of Ulsan College of Medicine, 
Ulsan; 
8Department of Internal Medicine, Chung-Ang 
University College of Medicine, Seoul; 
9Department 
of Internal Medicine, Kyungpook University College 
of Medicine, Daegu; 
10Department of Internal 
Medicine, Pusan National University College of 
Medicine, Busan; 
11Department of Internal Medicine, 
Korea University College of Medicine, Seoul, Korea 
Received: 14 March 2011
Accepted: 1 November 2011
Address for Correspondence:
Hoon Jai Chun, MD
Department of Internal Medicine, Korea University College of 
Medicine, 73 Inchon-ro, Seongbuk-gu, Seoul 136-075, Korea 
Tel: +82.2-920-6555, Fax: +82.2-953-1943
E-mail: drchunhj@chol.com
This study was supported by Janssen Korea Ltd., Seoul, Korea. 
The funding source had no role in the analysis and interpretation 
of data or in the decision to submit the manuscript for 
publication. The authors have no competing interests and no 
financial relationship with the pharmaceutical company. 
http://dx.doi.org/10.3346/jkms.2011.26.12.1613  •  J Korean Med Sci 2011; 26: 1613-1618
ORIGINAL ARTICLE
Gastroenterology & Liver Disease
INTRODUCTION
Gastroesophageal reflux disease (GERD) is a common gastro-
intestinal disease in Asia as well as in the West (1, 2). Studies have 
reported that 10%-20% of the adult Western population experi-
ence typical GERD symptoms (heartburn and/or regurgitation) 
at least once per week (1). The prevalence of GERD in adult Ko-
reans is reported to be 3.5%-8.5% (3-5). The prevalence of GERD 
appears to be increasing in Korea. This increase has been possi-
bly attributed to changes in diet, an increasing aged population, 
the increasing frequency of endoscopic examinations, and the 
widely spreading knowledge on GERD.
  The Montreal definition describes GERD as a condition that 
develops when the reflux of gastric contents causes troublesome 
symptoms and/or complications (6). A number of regional and 
international guidelines and recommendations for the manage-Lee KJ, et al.  •  Practice Pattern for GERD
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ment of GERD have been published. The Genval workshop re-
port on reflux disease management, published in 1999 (7), and 
the Asia-Pacific consensus on the management of GERD, pub-
lished in 2008 (8), are considered to be useful references for the 
management of GERD. Previous studies show that proton pump 
inhibitors (PPIs) are the most effective drug for patients with 
GERD (7, 8). Actually, PPIs are known to be most commonly 
prescribed for the treatment of GERD. However, the prescrip-
tion pattern of PPIs in patients with GERD may be different be-
tween countries, which is partly attributed to the economic sit-
uation or the health insurance system. In Korea, national health 
insurance covers the cost for the medication prescribed in hos-
pitals and clinics according to the insurance reimbursement 
guideline. Accordingly, the prescription pattern of PPIs used for 
the treatment of GERD is substantially influenced by the insur-
ance reimbursement guideline. 
  Thus, the aim of this study was to document practice pattern 
of gastroenterologists for the management of GERD patients 
under the minimal influence of the insurance reimbursement 
guideline. 
MATERIALS AND METHODS
This study was a multicenter prospective observational study 
conducted in Korea. Fifty-six gastroenterologists at 51 second-
ary and tertiary care hospitals representing most regions of Ko-
rea participated in the study. We chose the hospitals in the con-
sideration of the population living in that region. Fig. 1 shows the 
distribution of those hospitals. All participating gastroenterolo-
gists were required to recruit about 20 consecutive eligible pa-
tients who complained of typical GERD symptoms (heartburn 
and/or regurgitation). Patients were eligible for inclusion in this 
study if they were aged ≥ 18 yr and had typical GERD symptoms 
(heartburn and/or regurgitation) at least once per week over the 
previous 7 days with or without esophagitis. Endoscopy and 24-
hr esophageal pH monitoring were not essential for inclusion. 
Patients were excluded from participation if they had taking PPIs 
or histamine 2 receptor blocking agents within the previous 4 
weeks. The other exclusions were hypersensitivity to the active 
ingredient of PPIs and the presence of organic diseases such as 
gastrointestinal cancer, severe liver disease, pancreatic disease, 
peptic ulcer, inflammatory bowel disease, severe renal impair-
ment, or severe respiratory disease. 
  This study was observational and descriptive in nature. Thus, 
we tried to reduce the influence of the study on the routine clin-
ical practice for enrolled patients. The only thing that was affect-
ed by the study protocol was to choose a PPI. In order to mini-
mize the influence of the insurance reimbursement guideline 
on the use of PPIs, we recommended the use of rabeprazole (Pa-
riet, Janssen Korea Ltd., Seoul, Korea) for patients in whom PPI 
treatment should be considered for the management of GERD 
symptoms, because rabeprazole is the only PPI of which both 
full-dose and half-dose are permitted for the initial and mainte-
nance treatment of GERD, irrespective of the presence of ero-
sive esophagitis, in the national insurance reimbursement guide-
line. The others associated with the treatment for patients en-
rolled in the study had not been set by the study protocol. Par-
ticipating gastroenterologists were asked to carry out their rou-
tine practice at their own decision. The maximum observation 
period for the study was 16 weeks. During the study period, gas-
troenterologists followed their usual practice of patient care; the 
severity of symptoms and medications prescribed were recorded 
at each visit, using a web-based electronic data capture system. 
At the visit for inclusion, demographic data and information on 
the patient’s symptoms, previous investigations for GERD, and 
treatment received were documented. In addition, the frequency 
(days/week) and severity (0, none; 1, mild; 2, moderate; 3, se-
vere) of symptoms over the previous 7 days were assessed. When 
esophagogastroduodenoscopy (EGD) or 24-hr esophageal pH 
monitoring had been performed for the evaluation of GERD 
symptoms, its results were reviewed. 
  Since this study was not a clinical trial, there was no hypothe-
sis for the determination of the adequate sample size. Nonethe-
less, a sample size of 1,120 patients (20 patients per a gastroenter-
ologist) was planned. A subgroup analysis was carried out using 
the chi-squared test and Student’s t-test. The statistical analysis 
Fig. 1. The number of participating hospitals in each region. Lee KJ, et al.  •  Practice Pattern for GERD
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was performed using SPSS for Windows version 11 (SPSS Inc., 
Chicago, IL, USA).
Ethics statement
The study was approved by each of the institutional review boards 
of the hospitals where the principal investigator (approval num-
ber: 4-2008-0201) and other investigators belonged. Each pa-
tient received information on the study design such as data han-
dling and aims of the study. Informed consent was obtained. 
This study was an observational study and designed to have as 
little impact as possible on the management of patients. 
RESULTS
Baseline data  
Fifty-six gastroenterologists at 32 secondary and 19 tertiary care 
hospitals participated in the study. A total of 1,197 patients (523 
males, 44%) of mean age 53.1 ( ± 13.6) yr were recruited. Fifty-
seven percent of them were enrolled at secondary care hospitals 
and the others (43%) at tertiary care hospitals. At the time of en-
rollment, 479 patients (40%) had previous EGD results and 382 
patients (32%) underwent EGD before the start of medications. 
Thirty-six percent of those who had EGD results showed erosive 
esophagitis, and 3% had Barrett’s esophagus. At the time of en-
rollment, 6 patients had previous results of 24-hr esophageal pH 
monitoring. Seven patients underwent 24-hr esophageal pH 
monitoring during the evaluation period before the start of med-
ications, all of whom had atypical GERD symptoms and history 
of previous treatment for GERD symptoms. Baseline data and 
symptoms on patients enrolled in the study are shown in Table 
1 and 2, respectively. The most common accompanying symp-
tom was chest pain, followed by postprandial fullness, globus, 
belching, nausea, abdominal pain, early satiety, sore throat, 
chronic cough, hoarseness, dysphagia, vomiting, and odyno-
phagia in the order of prevalence. 
Treatment patterns 
During the 16-week study period, the mean total number of vis-
its per patient was 3.4 ( ± 1.4, ranged 1-6). PPIs were prescribed 
in 1,037 patients (87% of the study patients). Fig. 2 shows the to-
tal duration of PPI treatment in study subjects. The total dura-
tion of PPI treatment during the study period was ≤ 2 weeks in 
2%, > 2 weeks and ≤ 4 weeks in 9%, > 4 weeks and ≤ 8 weeks in 
Table 2. Baseline symptoms of the patients enrolled in the study
Symptoms   No.
Median severity 
score
Frequency (times/wk) 
Mean (SD)
Heartburn 928 1.9 4.5 (3.2)
Regurgitation 861 1.8 4.6 (4.3)
Chest pain 379 1.7 4.0 (2.6)
Postprandial fullness 325 1.7 4.9 (4.0)
Globus  322 1.8 5.1 (3.7)
Belching 289 1.7 5.0 (3.8)
Nausea 198 1.6 4.7 (3.5)
Abdominal pain 194 1.7 4.3 (3.3)
Early satiety 183 1.6 5.4 (4.9)
Sore throat 155 1.6 4.6 (3.7)
Chronic cough 154 1.6 5.1 (4.0)
Hoarseness 140 1.5 4.7 (3.9)
Dysphagia  103 1.5 4.9 (3.6)
Vomiting   73 1.6 3.8 (2.9)
Odynophagia    36 1.4 3.4 (2.2)
Severity score (0, none; 1, mild; 2, moderate; 3, severe); SD, Standard deviation.
Table 3. Comparison of the total number of visits and total duration of proton pump 
inhibitor (PPI) treatment during the 16-week observational period between patients 
with and without erosive esophagitis 
Variables
Without erosive 
esophagitis 
(n = 551)
With erosive 
esophagitis 
(n = 310)
P
Total number of visits 3.4 (1.5) 3.3 (1.3) 0.499
Total duration of PPI treatment  
   (days)
94.8 (33.4) 96.0 (32.8) 0.657
Mean (Standard deviation).
Table 1. Demographic and baseline characteristics of study patients 
Parameters Findings
Mean age (yr)                                                                         53.1 ± 13.6
Male:Female  523:674
Body mass index (kg/m
2) 23.4 ± 2.9
Previous medications (n = 454)
   Antacid, No. (%)
   Prokinetics, No. (%)
   Proton pump inhibitors, No. (%)
   H2-receptor blocking agents, No. (%)
 
211 (47)
378 (83)
  90 (20)
0
Endoscopic findings (n = 861)
   Normal, No. (%)
   LA-A, No. (%)
   LA-B, No. (%)
   LA-C, No. (%)
   LA-D, No. (%)
   Barrett’s esophagus, No. (%)
 
551 (64)
218 (25)
79 (9)
  7 (1)
  6 (1)
27 (3)
24-hr esophageal pH monitoring (n = 13)
   Pathologic esophageal acid exposure ( > 4.2%) 
   Positive symptom index
 
4
5
LA, Los Angeles classification of reflux esophagitis.
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Fig. 2. The total duration of PPI treatment during the 16-week study period. Lee KJ, et al.  •  Practice Pattern for GERD
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10%, > 8 weeks and ≤ 12 weeks in 5%, and > 12 weeks and ≤ 16 
weeks in 74%. A total of 748 patients were followed at week 16. 
The total number of visits and the total duration of PPI treatment 
did not significantly differ between patients with and without 
erosive esophagitis (Table 3). At the start of treatment, gastroen-
terologists prescribed rabeprazole 20 mg (full-dose) daily to 94% 
of the patients who received PPI treatment and rabeprazole 10 
mg (half-dose) daily to the remaining 6%. At the second visits, 
rabeprazole 20 mg daily was prescribed to 89% of those who were 
followed, and 10 mg daily to the remainder. At the third visit, the 
participating gastroenterologists prescribed rabeprazole 20 mg 
daily to 70% of those who were followed and 10 mg daily for the 
remaining 30%. During PPI treatment, prokinetics, mucosal pro-
tectives, antacids and histamine 2 receptor blocking agents were 
concomitantly used in 31%, 5%, 4%, and 1% of the patients, re-
spectively. 
DISCUSSION
Several international guidelines for the management of GERD 
are reported (6-8), but no domestic guidelines on clinical prac-
tice for patients with GERD have been issued yet in Korea. In the 
present study, we followed patients with typical GERD symp-
toms for 16 weeks, and observed gastroenterologists’ treatment 
patterns. The current study showed that PPIs are prescribed for 
the majority of patients with typical GERD symptoms and that 
Korean gastroenterologists preferred a full-dose PPI for both ini-
tial and maintenance treatment of GERD, irrespective of the pres-
ence of erosive esophagitis, rather than a half-dose PPI. This pro-
spective observational study was conducted at secondary or ter-
tiary care hospitals. Primary care clinics were excluded, because 
the aim of the study was to document gastroenterologists’ treat-
ment patterns. Patients with typical GERD symptoms who visit 
secondary and tertiary care hospitals participating in the study 
are treated by gastroenterologists. The institutions involved were 
selected on a nationwide scale in consideration of the number 
of regional population. Patients with typical GERD symptoms 
were recruited consecutively to reduce bias. EGD is relatively 
cheap in Korea because its cost is covered by national medical 
insurance. EGD was available in all institutions participating in 
the present study. Seventy-two percent of patients enrolled in the 
study had the results of EGD. Erosive esophagitis was observed 
in 36% of them, the majority of which was of grade LA-A or LA-B. 
Longitudinal studies conducted in Asia show an increase in the 
prevalence of GERD symptoms and reflux esophagitis (9-11). 
The ratio of erosive reflux disease (ERD) to nonerosive reflux dis-
ease (NERD) in Asia is believed to be lower than in the West (12). 
The ratio of ERD found in the present study was 36%, which seems 
to be getting comparable to that reported in the West. This may 
be partly attributed to the fact that the participating institutions 
were secondary and tertiary care hospitals.
  Since studies on the sensitivity and specificity of heartburn for 
predicting the presence of GERD are lacking in Korea, it is un-
certain whether heartburn is a definite marker of GERD in the 
Korean population. Erosive esophagitis found in patients with 
heartburn suggests that heartburn results from gastroesophageal 
reflux. Heartburn in patients without erosive esophagitis is con-
sidered to be NERD or functional heartburn. Functional heart-
burn is believed to be a different entity from NERD, particularly 
in terms of acid reflux patterns and the responsiveness to PPIs 
(13). Functional heartburn can be diagnosed when there are no 
abnormal acid or nonacid esophageal reflux, no symptom cor-
relation with reflux, and no response to PPIs (14). Abnormal acid 
or nonacid reflux can be determined using a 24-hr esophageal 
pH/impedance monitoring. Esophageal pH monitoring was 
available in 28 institutions (55% of the participating institutions). 
However, only 1% of the study patients underwent 24-hr ambu-
latory esophageal pH monitoring, which suggests that this test 
is not commonly performed even at secondary and tertiary care 
hospitals. In general, PPI trial is recommended to be preceding 
esophageal pH monitoring, particularly in patients with typical 
GERD symptoms. In the present study, ambulatory esophageal 
pH monitoring was performed mainly in patients with atypical 
GERD symptoms and history of previous PPI treatment for GERD 
symptoms, which is in keeping with the current guidelines. 
  The Asian-Pacific experts for GERD reported a general con-
sensus that PPIs provide the most effective treatment for ERD 
and NERD (8). The consensus is based on previous studies show-
ing that PPIs are superior to histamine 2 receptor blocking agents 
in terms of healing esophageal mucosa and relieving heartburn 
symptoms in patients with GERD (15-17). In the present study, 
most of patients enrolled in the study received PPI treatment 
(87% of the study patients). Prokinetics were the most common-
ly used concomitant medications, which can be possibly sup-
ported by the positive value of prokinetics in the treatment of 
GERD (18, 19) and substantial overlap between GERD symp-
toms and dyspepsia (5, 20). Our findings of the present study 
that 27% and 15% of the patients with typical GERD symptoms 
had postprandial fullness and early satiety, respectively, dem-
onstrate overlap between GERD symptoms and dyspepsia. 
  The Asian-Pacific consensus includes statements on the dura-
tion of PPI treatment for ERD and NERD as follows; “NERD pa-
tients require more than 4 weeks of initial continuous PPI ther-
apy and ERD patients need a minimum of 4-8 weeks of initial 
continuous PPI therapy” (8). It is difficult to determine timing to 
change initial treatment to maintenance treatment. According 
to the guidelines, maintenance treatment usually begins after 4 
weeks of initial treatment in NERD patients and after 8 weeks of 
initial treatment in patients with ERD. The influence of national 
health insurance system on the use of drugs is too big in Korea, 
because it covers all patients visiting hospitals due to GERD symp-
toms. Based on the national health insurance reimbursement Lee KJ, et al.  •  Practice Pattern for GERD
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guideline, full-dose of most PPIs, except rabeprazole, is permit-
ted only for the initial treatment of ERD, but not for the initial 
treatment of NERD and the maintenance treatment of ERD and 
NERD. According to that guideline, only half-dose PPI can be 
used for the initial treatment in patients with GERD symptoms 
who have no endoscopic findings and in NERD patients, and for 
the maintenance treatment of GERD. Thus, practice pattern is 
prone to be distorted by the reimbursement guideline. Rabepra-
zole is the only PPI of which both full-dose and half-dose are per-
mitted for the initial and maintenance treatment of ERD and 
NERD under the Korean health insurance system. So, in order 
to reduce distortion or variability in the clinical practice for GERD 
patients due to the national health insurance reimbursement 
guideline, we made a decision to recommend rabeprazole when 
PPI treatment is required for the enrolled patients. Since our main 
aims were to investigate the prescription pattern on the dosage 
of PPIs used for the treatment of GERD and to know whether 
Korean gastroenterologists keep the international guideline for 
the treatment of GERD, we tried to reduce the influence of the 
national health insurance reimbursement guideline and the 
study protocol. Thus, treatment for patients enrolled in the study 
had not been set by the study protocol, and participating gastro-
enterologists carried out their practice at their own decision.
  Given that rabeprazole 20 mg daily was used as initial treat-
ment in 94% of the patients who received PPI treatment, the ma-
jority of Korean gastroenterologists appear to prefer a full-dose 
PPI for the initial treatment of GERD, irrespective of the presence 
of erosive esophagitis. Gastroenterologists participating in this 
study tended to use a full-dose PPI without step-down of the 
dose. These points are not in keeping with the insurance reim-
bursement criteria, which might be attributed to a high propor-
tion of GERD patients requiring a long-term treatment of a full-
dose PPI. In the present study, the mean duration of continuous 
PPI therapy during the 16-week observational period was 96 and 
95 days in patients with and without erosive esophagitis, respec-
tively. In the present study, 62% of the study patients were con-
tinuously treated with PPIs until the end of the study period. Par-
ticipating gastroenterologists were allowed to prescribe only ra-
beprazole, either 10 mg or 20 mg, if they want to use PPI. Rabe-
prazole is the only PPI that both dosages are permitted to be used 
in the maintenance therapy according to the reimbursement 
guideline. Accordingly, they appear to choose the PPI dosage 
mainly based on the treatment efficacy. If other PPIs would have 
selected for this study, they might have prescribed according to 
the reimbursement guideline, irrespective of the treatment effi-
cacy. One of our aims was to investigate drug compliance, but 
we found that drug compliance was impossible to investigate, 
because many patients were not followed during the study pe-
riod. Since this was an observational study, follow-up was not 
controlled by the study protocol. So, follow-up loss was not pre-
vented, and drug compliance could not be investigated. Accord-
ing to the study design, participating gastroenterologists were 
able to make a decision for tests and treatment for the enrolled 
patients at their discretion. Thus, our findings suggest that many 
Korean patients with typical GERD symptoms need a long-term 
treatment of a full-dose PPI. 
  In conclusion, endoscopy is commonly performed for the eval-
uation of GERD symptoms, but 24-hr esophageal pH monitor-
ing is not. A full-dose PPI is preferred for the initial and mainte-
nance treatment of GERD under the minimal influence of the 
insurance reimbursement guideline, which may reflect a high 
proportion of GERD patients requiring a long-term treatment 
of a full-dose PPI. The management guideline appropriate for 
Korean patients with GERD is required. 
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